Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 30

Results For "CAS"

1859 News Found

Yatharth Hospitals acquires Shantived Hospital in Agra for Rs. 260 Cr
Healthcare | September 14, 2025

Yatharth Hospitals acquires Shantived Hospital in Agra for Rs. 260 Cr

Shantived Hospital generated revenue of around Rs 50 crore in FY2025


Aarti Drugs receives order from MPCB for closure of process at Tarapur unit
News | September 12, 2025

Aarti Drugs receives order from MPCB for closure of process at Tarapur unit

The HCl gas is generated continuously which is absorbed in the water scrubber using a chilled falling film system


Novartis to acquire Tourmaline Bio for $1.4 billion
News | September 10, 2025

Novartis to acquire Tourmaline Bio for $1.4 billion

Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease


Glenmark initiates multi-country Phase 3 clinical trial for Envafolimab in resectable Stage III NSCLC
Clinical Trials | September 06, 2025

Glenmark initiates multi-country Phase 3 clinical trial for Envafolimab in resectable Stage III NSCLC

The company has received approval from DCGI to begin patient enrolment and dosing in the country


DPIIT signs MoU with Pfizer to strengthen India’s healthcare innovation ecosystem
Startup | September 05, 2025

DPIIT signs MoU with Pfizer to strengthen India’s healthcare innovation ecosystem

Under the partnership, the Pfizer INDovation program will empower DPIIT-recognized startups with grants of up to Rs. 60 lakhs each, along with a tailored 18-month incubation program delivered by Social Alpha


MedTech Expo 2025: ICMR licenses nine technologies to 17 industry partners
News | September 05, 2025

MedTech Expo 2025: ICMR licenses nine technologies to 17 industry partners

These licenses are given in areas of infectious disease diagnostics, immunodiagnostics, and vaccine development


Syntegon reports H1 2025 EBITDA higher by 41% to €127 million
News | September 04, 2025

Syntegon reports H1 2025 EBITDA higher by 41% to €127 million

Free cash flow also reached €63 million, representing an 11 percent increase compared to the high benchmark set in 2024